The following Frequently Asked Questions (FAQs) focus on the issues that impact the research community. There will be further updates as more information becomes available. If you have any questions or require further details, please email and a member of the R&D Team will respond.

What is the Trust plan with respect to Research where the Trust is Sponsor?

Please see our updated ‘Restart, Reset and Recovery in clinical research’ guidance published on 11th May 2020 on

I am interested in taking forward some research into COVID-19, what do I need to do?

The National Institute for Health Research (NIHR) is working with partners across the health and care system to ensure that the Government is making best use of the limited resource and capacity available to support research into COVID-19.

A single national process has been set up to allow the Chief Medical Officer (CMO)/Deputy Chief Medical Officer (DCMO) for England to draw on expert advice to prioritise the COVID-19 studies which hold the most potential for tackling the challenges (Department of Health and Social Care’s expedited Urgent Public Health prioritisation).

This process will cover funded studies, irrespective of whether they are funded by the public sector, industry or charities; also, in partnership with UKRI, studies that require funding. It aims to prevent duplication of effort and to ensure that the capacity of the health and care system to support research is not exceeded.

Local CRNs, R&D Departments or healthcare sites should not be contacted directly with any new COVID-19 studies. Central, coordinated communications via the NIHR will enable the most effective delivery of the collective COVID-19 Urgent Public Health Research.

Details of the process and the new single point of entry for prioritising COVID-19 studies

The Trust has established a COVID-19 Research Team with PIs, Clinical Team Leads, Clinical Trials Co-coordinators and Governance support to ensure studies during this time are resourced and activated as rapidly as possible.

What about HRA Approvals under this process?

With regard to HRA approvals, researchers should first make an application through the national prioritisation process. They will be signposted for expedited regulatory approvals so that approval review can progress in parallel to the system of assessment leading to a view from CMO/DCMO on prioritisation.

Do we have to prioritise nationally prioritised studies?

Yes. All NHS Trusts, health and care providers and universities will need to prioritise support for studies which have been nationally prioritised. However, there are a large number of such studies and local prioritisation will also be necessary.

Live list of these studies

If we have the capacity to deliver COVID-19 studies that are not a national priority, can we do so?

Yes, only when this does not impact on the system’s ability to recruit participants and/or provide the resources (including staff, samples and data) needed to support nationally prioritised research. Organisations will be expected to pause any local studies that impede their ability to contribute to national research efforts.

What is happening with my study if it is a non COVID-19 study?

Until further notice, the NIHR Clinical Research Network is pausing the site set up of any new or ongoing studies at NHS and social care sites that are not nationally prioritised COVID-19 studies.

During this time, the MHRA and HRA will continue to provide an approvals service for all studies, prioritised in accordance with the national situation, ensuring site set-up can restart promptly in due course.

The NIHR Clinical Research Network will not be assessing any new commercial or non-commercial studies for CRN Support (with the exception of nationally sponsored COVID-19 studies received through the Department of Health and Social Care’s expedited Urgent Public Health processes).

The Trust, through the NJRO, will continue to support new commercial feasibility requests and non-commercial attribution support for non-commercial studies. Please be mindful that there may be delays during this period.

How will research delivery and support staff be impacted due to COVID-19?

In the event that COVID-19 places extreme pressure on NHS services, research delivery and support staff and facilities may be redeployed to support clinical services. Any redeployment will be agreed by the R&D Senior Management Team and take into account qualifications, skills and experience of research staff as well as the need to ensure there is sufficient capacity to deliver prioritised COVID-19 research.

At this time the Trust will not be allowing any external parties on the premises to conduct monitoring visits. Our research teams will continue to support central monitoring where this is deemed essential to the patient’s safety and/or treatment regime. Please note that this may change at short notice due to clinical demands.

We cannot send out source data via e-mail, PDF or other electronic means and it is also not possible to allow external parties access to our e-record systems.

How do we deal with any Urgent Safety Measures during this time?

Urgent Safety Measures (USMs) to trials that continue to follow-up must be reported in the usual way and CIs and PIs need to report any USM to sponsor immediately. Please refer to NJRO-GEN-SOP-002 ‘Protocol Deviations, Violations, Waivers and USMs in studies sponsored and hosted by NuTH FT’ available via

To note: Regulation 3 amends the Medicines for Human Use (Clinical Trials) Regulations 2004 to allow for notice of USMs to be given as soon as possible to the licensing authority and an ethics committee. Prospective protocol waivers are unacceptable and should not be used to change a trial due to the pandemic (for example eligibility, patient safety and/or difficulties in assessments). CIs should discuss with R&D and consider use of USM, temporary halts or patient discontinuation.

Due to the current situation, we are not able to fully adhere to Trust SOPs. What do we do during this time?

Where possible, all applicable SOPs should be followed and are available for review at It is understood that, in some cases, deviations to current SOPs may be required to ensure patient safety during a pandemic. The NJRO have produced a COVID-19 deviation to SOPs document (also available on the website) that all Trial staff should familiarise themselves with.

What if a participant cannot complete key safety checks?

All options should be explored for safety follow-ups; in some cases it may be necessary for the participant to travel to site, for example for bloods. If the participant cannot travel and there is no other option to support the visit then formally withdrawing the patients should be considered. Please speak with your study Sponsor before making a decision to withdraw.

My study has been suspended and I may not be able to meet the contractual obligations

It is understood that the temporary suspension of research due to COVID-19 may make it difficult to meet contractual obligations. This is a particular concern for commercial research.

Most contracts follow model agreements for commercial and non-commercial research and therefore Force Majeure clauses in contracts could be enforced. If there are any concerns regarding commercial research contracts or studies, please contact the NJRO Team via

My study is time and funding limited – what do I do if I need to extend?

Discussions are already underway with major funders including NIHR, UKRI, AMRC and others at a national level.

Early indications are that funders will be flexible in their approach and a comprehensive list of funder statements is currently in development and will be available shortly.

We are looking to co-ordinate these discussions with major funders on behalf of Newcastle University and the Trust. Please liaise with the Grants & Contracts Team if you have any concerns about your specific award via

For internally funded research including RCF and DT accounts, where expenditure cannot be incurred in the intended Financial Year, the relevant budget holders, with support from the Research Senior Management Team, will need to review the availability of funds in the next Financial Year.

I am, or have staff on fixed-term contracts – what does this mean for them?

Depending on the nature of your research, the duration of the restrictions and the need to ensure front line clinical services are supported, we fully appreciate that productivity may be adversely affected and there may be a case to extend staff on fixed-term contracts.

Work is ongoing at national level asking for urgent consideration of steps to protect researchers in training. Any updates will be posted as soon as possible.

I am on a Fellowship and I have been asked to return to Clinical Duties – what does this mean for me and my Fellowship?

We recognise at this time of responsiveness to COVID-19 there are concerns regarding the practicalities of pausing research programs to return to clinical duties.

The Trust is acutely aware of the importance of research informing clinical practice at a time like this and there have inevitably been questions related to how we might support colleagues who are undertaking research fellowships at various stages.

This comes alongside full support from government, the health services in all the devolved nations and professional bodies. Major research funders have also come together to show that they also support this. These funders will do all they can to mitigate the impact of lost time on existing fellowships and grant awards and also the reduced capability to submit grants at  this time

In light of the emerging advice, the Trust is recommending the following guidance:

  • When current programmes are pausedto enable a return to frontline practice, individuals are asked to discuss and manage this within their own clinical departments, through line managers and academic supervisors where appropriate. The relevant university guidelines should be followed in requesting any pause to a specific academic programme.
  • Those holding fellowships who are medics have all been contacted by their major funders to offer their support. NIHR, UKRI and the Wellcome Trust are all supportive and should meet excess incurred costs. Work is ongoing with other funders at the present time to determine how any excess incurred costs will be covered.
  • Careful monitoring will be required to enable the accurate capture of time off-programme and clinical hours worked. For clinical staff employed on a substantive Newcastle University contract with Trust Honorary Status, please fill in the form which can be accessed through your Newcastle University e-mail account. For clinical staff employed on a substantive Trust contract, please fill in the proforma which can be found at This is to ensure that we can support, oversee and inform a timely and straightforward process of restarting in the future.

In the event of a programme extension incurring additional academic costs, this will need to be negotiated with the academic institution and your funder on a case by case basis at the time of restart. We will support this.

Can I still submit an application for external funding which is not COVID-19 related?

Yes – preparation of research grant applications is encouraged. The teams supporting the application process are, in the main, now working remotely but continue to have access to the systems needed to facilitate submission. The current process for submission should continue to be followed.

Please be mindful of the need to show consideration, patience and understanding as colleagues move to different ways of working and cover for those who may become unwell during this challenging time.

I have been successful in a research award and concerned about the start date

It is recommended that if you are concerned about the start date of your award, please liaise with the funder to agree a revised start date. Any agreed amendments to start dates should be sent to so the necessary changes can be made.

  • Newcastle University has paused all new staff recruitment until at least 31st July 2020. Exceptions will be granted on a case by case basis.
  • For those staff on fixed-term contracts, Newcastle University has agreed to extend all contracts to 31st July 2020.
  • If you have any queries regarding any of the above, please contact the Faculty of Medical Sciences People Services team on
  • The Trust continues to recruit staff at the present time, but please be mindful of the current circumstances when considering your recruitment and selection plan.

It is important to take all of the above into account when considering liaising with funders over any revised start date.

Will REF 2021 preparations be affected?

Yes. REF 2021 will be put on hold until further notice to allow institutions to divert staff resource to other critical areas, including those working in clinical and health-related fields.

The submission deadline on 27 November 2020 will no longer apply, and a new submission deadline will be announced no later than eight months prior to the deadline.

The funding bodies recognise the significant effort that has been invested so far by institutions in preparations for the current REF cycle. As a result, the REF staff census date (31 July 2020) remains unchanged at the present time.

When there is greater clarity about the period of serious disruption to universities, consultations will be held on the adapted details of the framework. This will be as light touch as possible, in view of these challenging times.

Whilst REF2021 has been put on hold until further notice, work is still ongoing at Newcastle University to prepare the documentation for submission. As the majority of this documentation can be completed electronically, it is still possible to be involved. If you receive any requests from the REF team at the University, for information or updates, please respond.